Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 726 participants.

Also called NCT07734792

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 726 participants (planned count) (from the registry)
Sponsor
yifang zhu (from the registry)
Registry
  • NCT NCT07734792
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07734792. Randomized; single masking; primary purpose treatment. Start 2026-09-26 (actual); primary completion 2028-05-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial
Acronym
TOPAZ
Condition
Acute Ischemic Stroke (AIS)
Intervention (Drug)
Tirzepatide
Intervention (Other)
Standard Medical Care (SMC)
Lead sponsor
yifang zhu (class: other)

Record details

Record id
cardio:ct-nct07734792
Content hash
4e1f844ad57f8860dae870b1f64c71ed45d1c68fcc4061fa550f9d5c995e028a